{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:31:19Z","timestamp":1792560679774,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had an important impact on dermatology practice, posing diagnostic and therapeutic challenges especially in patients with inflammatory and autoimmune skin disorders. Disease-specific and nonspecific cutaneous manifestations have been increasingly reported in the spectrum of COVID-19 but the influence of the infection on pre-existing dermatologic diseases has not been clearly defined. There has been a debate in the literature as to whether patients suffering from autoimmune dermatoses, including cutaneous lupus erythematosus (CLE), are at increased risk of SARS-CoV-2 infection, as well as if they experience worsening of their lupus erythematosus (LE)-related clinical symptoms. This article reports on a case of Rowell syndrome occurring after COVID-19 in a 67-year old woman with pre-existing chronic CLE manifesting with few discoid lesions on the face, scalp, and upper chest, successfully controlled with topical corticosteroids and photoprotection. Erythema multiforme (EM)-like eruption developed approximately two weeks after the SARS-CoV-2 infection, the latter being confirmed by positive nasopharyngeal swab and successfully treated with systemic antibiotics and antiaggregants. Diffuse hair loss and patches of cicatricial alopecia were also present upon scalp examination. Laboratory workup, including routine tests, histologic, immunofluorescent, and serologic investigations, was supportive to the diagnosis. Administration of topical and systemic corticosteroids along with peroral hydroxychloroquine resulted in the progressive improvement of the cutaneous lesions. Rowell syndrome is a rare entity in the spectrum of LE, characterized by EM-like lesions, photosensitivity, and positive antinuclear and anti-Ro antibodies, that is currently considered to be a variant of subacute CLE (SCLE). Several cases of SCLE have been described in association with medications, including anti-SARS-CoV-2 vaccines but only a few reports incriminate the infection itself as a potential exacerbating factor. Based on the clinical course of the disease, we suggest that the observed Rowell syndrome-like flare of CLE was related to the COVID-19 infection in this patient.<\/jats:p>","DOI":"10.3389\/fmed.2022.815743","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T05:38:57Z","timestamp":1644817137000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Case Report: Rowell Syndrome\u2013Like Flare of Cutaneous Lupus Erythematosus Following COVID-19 Infection"],"prefix":"10.3389","volume":"9","author":[{"given":"Kossara","family":"Drenovska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mateeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snejina","family":"Vassileva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1177\/09612033211045057","article-title":"COVID-19 in systemic lupus erythematosus: A pooled analysis and systematic review of case reports and series","volume":"30","author":"Sakthiswary","year":"2021","journal-title":"Lupus."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/ijd.15189","article-title":"Covid-19 pandemic and the skin","volume":"59","author":"Drenovska","year":"2020","journal-title":"Int J Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.clindermatol.2020.12.013","article-title":"Autoimmune connective tissue diseases in the COVID-19 pandemic","author":"Dourmishev","year":"2021","journal-title":"Clin Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1001\/archderm.1963.01590200064012","article-title":"Lupus erythematosus and erythema multiforme-like lesions","volume":"88","author":"Rowell","year":"1963","journal-title":"Arch Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/archderm.115.12.1409","article-title":"Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset","volume":"115","author":"Sontheimer","year":"1979","journal-title":"Arch Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S0190-9622(00)90141-5","article-title":"Subacute cutaneous lupus erythematosus presenting with generalized poikiloderma","volume":"42","author":"Pramatarov","year":"2000","journal-title":"J Am Acad Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0961203311430513","article-title":"The last world on the so-called \u201cRowell's syndrome\u201d","volume":"21","author":"Antiga","year":"2012","journal-title":"Lupus."},{"key":"B8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/000155500750012289","article-title":"Erythema multiforme-like subacute cutaneous lupus erythematosus","volume":"80","author":"Massone","year":"2000","journal-title":"Acta Derm Venereol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jaad.2011.10.012","article-title":"Erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis associated with lupus erythematosus","volume":"3","author":"Torchia","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/3-540-26581-3_6","article-title":"Clinical manifestations of cutaneous lupus erythematosus","volume":"6","author":"Kuhn","year":"2008","journal-title":"J Dtsch Dermatol Ges."},{"key":"B11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.autrev.2012.08.019","article-title":"Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)","volume":"12","author":"Biazar","year":"2013","journal-title":"Autoimmunity Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.autrev.2004.10.003","article-title":"Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings","volume":"4","author":"Sontheimer","year":"2005","journal-title":"Autoimmun Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2133.2011.10397.x","article-title":"Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart","volume":"165","author":"Marzano","year":"2011","journal-title":"Br J Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.autrev.2013.09.004","article-title":"The cryptic interplay between systemic lupus erythematosus and infections","volume":"13","author":"Rigante","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/jmv.26513","article-title":"Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient","volume":"93","author":"Slimani","year":"2021","journal-title":"J Med Virol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"102883","DOI":"10.1016\/j.autrev.2021.102883","article-title":"Rheumatological complications of Covid 19","volume":"20","author":"Zacharias","year":"2021","journal-title":"Autoimmun Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s10067-021-05691-x","article-title":"COVID-19 and the clinical course of rheumatic manifestations","volume":"40","author":"Ahmed","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"102597","DOI":"10.1016\/j.autrev.2020.102597","article-title":"Covid-19 and autoimmunity","volume":"19","author":"Ehrenfeld","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/RHU.0000000000001531","article-title":"A case of systemic lupus erythematosus flare triggered by severe coronavirus disease 2019","volume":"26","author":"Raghavan","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00296-021-04794-7","article-title":"Can the SARS-CoV-2 infection trigger systemic lupus erythematosus?","volume":"41","author":"Gracia-Ramos","year":"2021","journal-title":"A case-based review Rheumatol Int."},{"key":"B21","first-page":"9695","article-title":"The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection","volume":"24","author":"Bonometti","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13256-020-02582-8","article-title":"Systemic lupus erythematosus manifestation following COVID-19: a case report","volume":"15","author":"Zamani","year":"2021","journal-title":"J Med Case Reports."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.41425","article-title":"Antiphospholipid antibodies in critically ill patients with COVID-19","volume":"72","author":"Xiao","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"606195","DOI":"10.1155\/2012\/606195","article-title":"Clinical and pathological roles of Ro\/SSA autoantibody system","volume":"2012","author":"Yoshimi","year":"2012","journal-title":"Clin Dev Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.20452\/pamw.16022","article-title":"Untypical presentation of cutaneous lupus in a young patient following COVID-19: differentiation of COVID toes","volume":"131","author":"Jaworek","year":"2021","journal-title":"Pol Arch Intern Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/bjd.19806","article-title":"COVID-19-associated cutaneous manifestations: does human herpesvirus 6 play an aetiological role?","volume":"184","author":"Abad\u00edas-Granado","year":"2021","journal-title":"Br J Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1111\/jdv.17225","article-title":"Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination","volume":"35","author":"Gambichler","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/ced.14858","article-title":"Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination","volume":"47","author":"Kreuter","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e15017","DOI":"10.1111\/dth.15017","article-title":"Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine","volume":"471","author":"Niebel","year":"2021","journal-title":"Dermatol Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e15114","DOI":"10.1111\/dth.15114","article-title":"Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine","volume":"34","author":"Joseph","year":"2021","journal-title":"Dermatol Therapy"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.815743\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T05:39:01Z","timestamp":1644817141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.815743\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":30,"alternative-id":["10.3389\/fmed.2022.815743"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.815743","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"article-number":"815743"}}